怀孕期间使用抗节律性药物:考虑因素和安全性概况
Marco Valerio Mariani1, Nicola Pierucci1,2, Vincenzo Mirco La Fazia2
1Department of Clinical Internal Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy.
Journal of cardiovascular development and disease
|August 28, 2024
概括
与怀孕有关的心律失常需要谨慎管理,因为对母亲和胎儿存在潜在风险. 怀孕期间使用抗节律药物 (AAD) 需要个性化治疗和密切监测以获得最佳结果.
科学领域:
- 心脏病学 心脏病学
- 孕产妇和胎儿医学 孕产妇和胎儿医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 怀孕涉及显著的生理和荷尔蒙变化,影响母亲和胎儿的健康.
- 心血管事件,特别是心律不整,在怀孕期间构成严重风险,特别是对于那些有先前存在的疾病.
- 了解怀孕期间心律失常的细微差别对于有效管理至关重要.
研究的目的:
- 提供有关怀孕个体心律不整的流行,治疗选择和预后的全面概述.
- 讨论与怀孕期间服用抗不律性药物 (AAD) 相关的安全性和潜在风险.
- 强调个性化治疗策略的重要性以及对患有心律失常的孕妇的警监测.
主要方法:
- 关于怀孕期间心律失常的流行病学的文献综述.
- 分析当前治疗方法来管理妊娠期间心律失常.
- 评估各种类型抗心律不良药在孕妇群体中的安全数据和潜在不良影响.
主要成果:
- 怀孕期间的心律失常会因为生理适应和潜在的药物相关风险而带来独特的挑战.
- 抗节律药物 (AADs) 可以穿过胎盘并进入母乳,可能导致产性,生长限制或早产.
- 不同类别的AAD表现出不同的安全性,需要根据个体患者的因素进行仔细选择.
结论:
- 个性化治疗计划对于管理孕妇心律失常是必不可少的.
- 在怀孕期间处方抗心律不良药时,对母亲和胎儿的密切监测至关重要.
- 优化孕产妇和胎儿的结果需要对怀孕背景下的心律失常管理有充分的了解.
相关概念视频
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
719
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
719
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
935
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
935
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
798
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
798
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
421
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
421
01:20Antiepileptic Drugs: Potassium Channel Activators
150
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
150